<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04755478</url>
  </required_header>
  <id_info>
    <org_study_id>OPEN THORUS</org_study_id>
    <nct_id>NCT04755478</nct_id>
  </id_info>
  <brief_title>LUS to Assess Lung Injury After Lung Lobectomy</brief_title>
  <acronym>OPEN THORUS</acronym>
  <official_title>Ultrasound Assessment of Aeration Changes After Lung Lobectomy: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General Universitario de Valencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General Universitario de Valencia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess whether lung ultrasound is able to detect lung injury&#xD;
      after lung resection surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative pulmonary complications (PPC) are common after lung resection surgery, with an&#xD;
      incidence that ranges between 11-32%. As PPC are associated with worse outcomes, many studies&#xD;
      aim to find predictors that identify high risk patients and prompt specific interventions&#xD;
      and/or monitoring and hence, improve outcomes. PPC result from lung injury inherent to lung&#xD;
      resection surgery. Lung aeration changes seen with lung ultrasound (LUS) could detect lung&#xD;
      injury and thus, identify patients at high risk of PPC. The underlying mechanisms of lung&#xD;
      injury are different in the dependent and non-dependent lung; oxidative stress in both lungs,&#xD;
      lung injury associated with one-lung ventilation in the dependent lung and&#xD;
      ischemia/reperfusion or surgical manipulation in the non-dependent lung. LUS evaluates the&#xD;
      dependent and non-dependent lung separately and so it can be valuable in understanding the&#xD;
      characteristics and intensity of lung injury in each lung specifically.&#xD;
&#xD;
      This is a prospective, single-centre, observational study in which 30 consecutive&#xD;
      participants with non-small cell lung cancer scheduled for lobectomy will be recruited.&#xD;
      Participants will be divided in two groups depending on the surgical approach. First group&#xD;
      will be lobectomy via thoracotomy. Second group will be lobectomy via VATS. Participants will&#xD;
      be recruited consecutively until there are 15 patients in each group. LUS will be performed&#xD;
      in each participant's operated and non-operated lung at three predefined time points: before&#xD;
      surgery, after extubation and 24 h after surgery. Each hemithorax will be divided into 6&#xD;
      areas: anterior, lateral and posterior, separated by the anterior and posterior axillary&#xD;
      lines, each divided into upper and lower zones. For each echographic examination, cineloops&#xD;
      of the most pathological findings in each area will be stored and analysed offline by two&#xD;
      independent and blinded anaesthesiologists. From these, a semiquantitative score, the&#xD;
      modified lung ultrasound score (mLUSS), will be calculated for each hemithorax to assess lung&#xD;
      aeration at each time point. The level of agreement for mLUSS will be tested. At the same&#xD;
      predefined time points blood plasma samples will be collected, flash-frozen and stored in&#xD;
      order to measure levels of the inflammatory mediators IL-6, IL-10 and TNFα.&#xD;
&#xD;
      The investigators hypothesise that LUS can detect lung injury after lung resection surgery.&#xD;
      The primary objective of the study is to assess changes in lung aeration after lung resection&#xD;
      with mLUSS. Secondary objectives are, first, to describe LUS findings after lung resection&#xD;
      surgery, second, to assess the ability of mLUSS to detect oxygenation changes after lung&#xD;
      resection and third, to compare the behaviour of inflammatory mediators in plasma with mLUSS&#xD;
      changes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mLUSS after lung resection.</measure>
    <time_frame>preoperative vs immediate postoperative period vs 24 hours after surgery.</time_frame>
    <description>The modified lung ultrasound score (mLUSS) ranges 0-36; the higher the score, the less aeration (worse).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LUS feasibility in the dependent and non-dependent lung.</measure>
    <time_frame>Preoperative vs immediate postoperative period vs 24 hours after surgery.</time_frame>
    <description>Percetage of patients in which ultrasound examination is feasible. There is no important surgical emphysema and/or the dressings or chest tubes do not preclude the feasibility of the examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in oxygenation (PAFI) after lung resection.</measure>
    <time_frame>Preoperative vs immediate postoperative vs 24 hours after surgery.</time_frame>
    <description>PAFI is the ratio between paO2 and fraction of inspired oxygen; the lower, the worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma cytokine IL-6 after lung resection.</measure>
    <time_frame>Preoperative vs immediate postoperative vs 24 hours after surgery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma cytokine IL-10 after lung resection.</measure>
    <time_frame>Preoperative vs immediate postoperative vs 24 hours after surgery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma TNFα after lung resection.</measure>
    <time_frame>Preoperative vs immediate postoperative vs 24 hours after surgery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood bone natriuretic peptide (BNP) after lung resection.</measure>
    <time_frame>Preoperative vs immediate postoperative vs 24 hours after surgery.</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lung Neoplasm</condition>
  <condition>Adult ALL</condition>
  <condition>Lung Injury</condition>
  <condition>Lung Inflammation</condition>
  <condition>Lung Ischemia/Hypoxia</condition>
  <condition>Postoperative Complications</condition>
  <condition>Postoperative Respiratory Complication</condition>
  <condition>Lung Cancer</condition>
  <condition>Thoracic</condition>
  <arm_group>
    <arm_group_label>Lung lobectomy via open thoracotomy</arm_group_label>
    <description>participants scheduled for lung lobectomy via open thoracotomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lung lobectomy via VATS</arm_group_label>
    <description>participants scheduled for lung lobectomy via video-assisted thoracoscopic surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thoracotomy</intervention_name>
    <description>Participants will undergo lobectomy via open thoracotomy at the discretion of the surgical team.</description>
    <arm_group_label>Lung lobectomy via open thoracotomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>VATS</intervention_name>
    <description>Participants will undergo lobectomy via VATS at the discretion of the surgical team.</description>
    <arm_group_label>Lung lobectomy via VATS</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood and plasma samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients assigned to a tertiary referral hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  ASA I-III&#xD;
&#xD;
          -  Non-small cell lung neoplasm&#xD;
&#xD;
          -  Elective lung lobectomy&#xD;
&#xD;
          -  Under one-lung ventilation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Respiratory tract infection the previous month&#xD;
&#xD;
          -  Diagnosed pulmonary fibrosis&#xD;
&#xD;
          -  Predicted FEV &lt; 40%&#xD;
&#xD;
          -  Surgery that includes resection of the thoracic wall or the diaphragm&#xD;
&#xD;
          -  Neoplasm metastasis&#xD;
&#xD;
          -  Obesity class II or more (BMI ≥ 35 kg/m^2)&#xD;
&#xD;
          -  Risk of malnutrition CONUT &gt; 1&#xD;
&#xD;
          -  Hemoglobin &lt; 10 g/dl&#xD;
&#xD;
          -  Chronic kidney failure: glomerular filtration &lt; 60 ml/min/m^2, nephrectomy, kidney&#xD;
             transplantation&#xD;
&#xD;
          -  Treatment with corticosteroids or immunosuppressive agents 3 months before surgery&#xD;
&#xD;
          -  Transfusion of blood products during the previous 10 days&#xD;
&#xD;
          -  Heart failure (New York Heart Association Functional Class 3 or 4) during the week&#xD;
             before surgery.&#xD;
&#xD;
          -  Heart valve diseases over stage B of the American College of Cardiology/American&#xD;
&#xD;
          -  Heart Association Task Force on Practice Guidelines 2014&#xD;
&#xD;
          -  Diastolic dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Broseta Lleó, Consultant</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario de Valencia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana Broseta Lleó, Consultant anaesthesiologist</last_name>
    <phone>656575897</phone>
    <email>ana.broseta@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana Broseta Lleó, Consultant</last_name>
    <phone>656575897</phone>
    <email>ana.broseta@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Broseta Lleó, Consultant</last_name>
      <phone>656575897</phone>
      <email>ana.broseta@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General Universitario de Valencia</investigator_affiliation>
    <investigator_full_name>Ana Broseta Lleó</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>thoracic surgery</keyword>
  <keyword>lung ultrasound</keyword>
  <keyword>cytokines blood</keyword>
  <keyword>lung injury</keyword>
  <keyword>postoperative complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

